Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
EW Stock Forecast 2026-2027
$81.44
Current Price
$47.30B
Market Cap
Buy 22
Hold 8
Sell 0
Wall St Analyst Ratings
Distance to EW Price Targets
+35.1%
To High Target of $110.00
+20.3%
To Median Target of $98.00
+3.1%
To Low Target of $84.00
EW Price Momentum
+4.1%
1 Week Change
-1.3%
1 Month Change
+15.4%
1 Year Change
-4.5%
Year-to-Date Change
-7.3%
From 52W High of $87.89
+18.7%
From 52W Low of $68.63
📊 TOP ANALYST CALLS
Did EW Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Edwards is one of their latest high-conviction picks.
Latest EW Stock Price Targets & Analyst Predictions
Based on our analysis of 38 Wall Street analysts, EW has a bullish consensus with a median price target of $98.00 (ranging from $84.00 to $110.00). The overall analyst rating is Strong Buy (8.6/10). Currently trading at $81.44, the median forecast implies a 20.3% upside. This outlook is supported by 22 Buy, 8 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Rick Wise at Stifel, projecting a 35.1% upside. Conversely, the most conservative target is provided by William Plovanic at Canaccord Genuity, suggesting a 3.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
EW Analyst Ratings
22
Buy
8
Hold
0
Sell
EW Price Target Range
Low
$84.00
Average
$98.00
High
$110.00
Current: $81.44
Latest EW Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for EW.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 13, 2026 | Mizuho | Anthony Petrone | Outperform | Maintains | $95.00 |
| Apr 6, 2026 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $92.00 |
| Feb 11, 2026 | Wells Fargo | Larry Biegelsen | Overweight | Maintains | $100.00 |
| Feb 11, 2026 | Goldman Sachs | David Roman | Buy | Maintains | $95.00 |
| Feb 11, 2026 | Truist Securities | Richard Newitter | Hold | Maintains | $89.00 |
| Feb 11, 2026 | BTIG | Marie Thibault | Buy | Reiterates | $103.00 |
| Feb 11, 2026 | Piper Sandler | Adam Maeder | Overweight | Reiterates | $100.00 |
| Jan 20, 2026 | Piper Sandler | Adam Maeder | Overweight | Maintains | $98.00 |
| Jan 20, 2026 | Stifel | Rick Wise | Buy | Maintains | $110.00 |
| Jan 12, 2026 | UBS | Danielle Antalffy | Neutral | Maintains | $95.00 |
| Jan 12, 2026 | Barclays | Matt Miksic | Overweight | Maintains | $104.00 |
| Jan 9, 2026 | TD Cowen | Joshua Jennings | Buy | Upgrade | $97.00 |
| Jan 7, 2026 | Stifel | Rick Wise | Buy | Maintains | $105.00 |
| Dec 18, 2025 | JP Morgan | Robbie Marcus | Overweight | Upgrade | $100.00 |
| Dec 17, 2025 | Canaccord Genuity | William Plovanic | Hold | Maintains | $87.00 |
| Dec 16, 2025 | Baird | David Rescott | Neutral | Maintains | $87.00 |
| Dec 11, 2025 | Citigroup | Joanne Wuensch | Buy | Maintains | $101.00 |
| Dec 8, 2025 | Barclays | Matt Miksic | Overweight | Maintains | $103.00 |
| Dec 5, 2025 | Truist Securities | Richard Newitter | Hold | Maintains | $92.00 |
| Dec 5, 2025 | Canaccord Genuity | William Plovanic | Hold | Maintains | $89.00 |
Edwards Lifesciences Corporation (EW) Competitors
The following stocks are similar to Edwards based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
EW
Edwards Lifesciences
mkt cap
47.04B
Edwards Lifesciences Corporation (EW) Financial Data
Edwards Lifesciences Corporation has a market capitalization of $47.30B with a P/E ratio of 44.7x. The company generates $6.07B in trailing twelve-month revenue with a 17.7% profit margin.
Revenue growth is +13.3% quarter-over-quarter, while maintaining an operating margin of +23.7% and return on equity of +10.4%.
Valuation Metrics
Market Cap
$47.30B
Enterprise Value
$43.52B
P/E Ratio
44.7x
PEG Ratio
-0.6x
Price/Sales
7.8x
Growth & Margins
Revenue Growth (YoY)
+13.3%
Gross Margin
+78.1%
Operating Margin
+23.7%
Net Margin
+17.7%
EPS Growth
-76.3%
Financial Health
Cash/Price Ratio
+8.9%
Current Ratio
3.7x
Debt/Equity
6.8x
ROE
+10.4%
ROA
+7.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Edwards Lifesciences Corporation (EW) Business Model
About Edwards Lifesciences Corporation
What They Do
Innovative medical devices for structural heart disease.
Business Model
The company develops and commercializes advanced medical devices, particularly focusing on transcatheter aortic valve replacement (TAVR) systems and hemodynamic monitoring solutions. It generates revenue by offering these breakthrough technologies to healthcare providers, improving patient care and procedural efficiency in cardiovascular treatments.
Additional Information
Founded in 2000 and headquartered in Irvine, California, the company collaborates with clinicians and researchers globally to advance innovations in heart care. Edwards Lifesciences plays a significant role in the medical device industry, focusing on enhancing patient outcomes and quality of life through minimally invasive procedures.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
16,000
CEO
Mr. Bernard J. Zovighian
Country
United States
IPO Year
2000
Website
www.edwards.comEdwards Lifesciences Corporation (EW) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Edwards Lifesciences' Q1 Earnings on Deck: Here's What to Expect
EW heads into Q1 earnings with TAVR strength, rising estimates and momentum in mitral and tricuspid therapies shaping expectations.
Apr 20, 2026
By Zacks Equity Research
Analyst Blog
Thermo Fisher Scientific (TMO) Earnings Expected to Grow: Should You Buy?
Thermo Fisher (TMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apr 16, 2026
By Zacks Equity Research
Tale of the Tape
Top Stock Reports for Eli Lilly, Mastercard & AMD
Eli Lilly rides strong GLP-1 demand and pipeline momentum, while Mastercard and AMD navigate mixed performance and rising competition pressures.
Apr 13, 2026
By Mark Vickery
Research Daily
Latest News
Quick Summary
Meta Platforms is making progress in social and data privacy policies. Edwards' transcatheter valve therapies show potential. The firm exited its Workday position to adjust software exposure.
Why It Matters
Meta's improved privacy measures could enhance user trust and compliance, impacting its stock positively. Edwards' valve therapies may outperform expectations, signaling growth potential. Workday's exit aligns with market trends.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Edwards Lifesciences (NYSE: EW) will announce Q1 2026 operating results on April 23, after market close, and host a conference call at 5:00 p.m. ET. Details available on their Investor Relations website.
Why It Matters
Edwards Lifesciences' upcoming earnings announcement and conference call will provide insights into its financial performance, impacting stock valuation and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
The firm initiated positions in Semtech, Tradeweb Markets, and SiTime, while increasing stakes in Edwards Lifesciences, Waters, and Arthur J. Gallagher, and exited Ares, CCC Intelligent Solutions, and Parsons.
Why It Matters
The initiation and termination of positions signal changes in investment strategies, reflecting confidence in some sectors while indicating potential concerns in others, impacting stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
The portfolio shifted focus from AI-vulnerable companies to those with stable growth, investing in Dick's Sporting Goods and exiting Ares Management due to liquidity and credit concerns.
Why It Matters
Shifting investments towards companies with strong growth potential signals a proactive strategy to mitigate AI disruption risks, while exiting Ares Management reflects caution amid credit market pressures.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Edwards Lifesciences (NYSE: EW) presented positive EVOQUE TTVR system data at ACC.26, showing significant patient benefits and lower mortality, expanding upon findings from ESC 2025.
Why It Matters
New positive data on Edwards Lifesciences' EVOQUE TTVR system suggests improved patient outcomes and lower mortality rates, potentially boosting the company's market value and investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Edwards Lifesciences: More Appeal For The Heart
1 month ago
Quick Summary
Edwards Lifesciences reported 11% revenue growth in 2025, guided for 8-10% growth in 2026, and forecasts TMTT sales to rise 40%. Valuation at 26x forward earnings with strong cash and buybacks.
Why It Matters
Edwards Lifesciences' strong growth and positive guidance indicate solid future performance, making it an attractive investment amid a favorable valuation and robust cash position.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About EW Stock
What is Edwards Lifesciences Corporation's (EW) stock forecast for 2026?
Based on our analysis of 38 Wall Street analysts, Edwards Lifesciences Corporation (EW) has a median price target of $98.00. The highest price target is $110.00 and the lowest is $84.00.
Is EW stock a good investment in 2026?
According to current analyst ratings, EW has 22 Buy ratings, 8 Hold ratings, and 0 Sell ratings. The stock is currently trading at $81.44. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for EW stock?
Wall Street analysts predict EW stock could reach $98.00 in the next 12 months. This represents a 20.3% increase from the current price of $81.44. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Edwards Lifesciences Corporation's business model?
The company develops and commercializes advanced medical devices, particularly focusing on transcatheter aortic valve replacement (TAVR) systems and hemodynamic monitoring solutions. It generates revenue by offering these breakthrough technologies to healthcare providers, improving patient care and procedural efficiency in cardiovascular treatments.
What is the highest forecasted price for EW Edwards Lifesciences Corporation?
The highest price target for EW is $110.00 from Rick Wise at Stifel, which represents a 35.1% increase from the current price of $81.44.
What is the lowest forecasted price for EW Edwards Lifesciences Corporation?
The lowest price target for EW is $84.00 from William Plovanic at Canaccord Genuity, which represents a 3.1% increase from the current price of $81.44.
What is the overall EW consensus from analysts for Edwards Lifesciences Corporation?
The overall analyst consensus for EW is bullish. Out of 38 Wall Street analysts, 22 rate it as Buy, 8 as Hold, and 0 as Sell, with a median price target of $98.00.
How accurate are EW stock price projections?
Stock price projections, including those for Edwards Lifesciences Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 21, 2026 6:03 PM UTC